We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
National Vision Gains 129.5% in a Year: What's Driving the Rally?
Read MoreHide Full Article
Key Takeaways
National Vision's shares jumped 129.5% in a year, beating an industry decline on Owned & Host gains.
EYE expands exam capacity using remote tech in about two-thirds of stores and hybrid exam pilots.
National Vision projects 2026 revenues of $2.033B-$2.091B and adjusted EPS of $0.85-$1.09.
National Vision (EYE - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 129.5%, outperforming the industry’s 12% decline. The S&P 500 composite has increased 23.1% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.
National Vision is a major optical retailer in the United States. As of June 28, 2025, the company operated through a diverse portfolio of 1,240 retail stores across four brands, along with associated omnichannel consumer websites. National Vision operates through one reportable segment, Owned & Host, which includes two owned brands — America’s Best Contacts and Eyeglasses (America’s Best) and Eyeglass World.
Factors Favoring EYE’s Share Price Growth
National Vision’s share price is trending upward, prompted by its strong market share gain in Owned & Host segment. The segment continues to gain from positive comparable store sales growth and new store openings. Of the two Owned brands, America’s Best remains the primary revenue driver.
The company is also driving improvements in Eyeglass World, bringing in a new leadership team earlier in 2025. Further, National Vision leverages remote capabilities to expand exam capacity, with approximately two-thirds of its store base now enabled with remote technology. Its remote hybrid pilot is also progressing well, with more in-store doctors now trained to perform remote exams in other locations. Simultaneously, National Vision is implementing electronic health records to drive expanded capacity, improve in-store efficiencies and improve the patient experience. A solid fourth-quarter performance is also expected to contribute further.
Investors are currently focused on the company’s ongoing strategic transformation. According to management, the transformation initiatives are gaining traction and the strategic focus on key customer segments is driving improvement in its comparable sales. Newly added premium frames like Lam, Ted Baker, Jimmy Choo, HUGO Boss are selling faster than expected. Additionally, the new, refreshed branding unveiled in August 2025 was a major milestone in National Vision's transformation journey.
Meanwhile, National Vision’s 2026 outlook looks encouraging. Net revenues are projected in the range of $2.033-$2.091 billion. Adjusted EPS is estimated to be between 85 cents and $1.09.
Operationally, in the fourth quarter, gross margin expanded 45 basis points (bps) despite a 13.9% rise in the cost of revenues. Also, the operating margin expanded 186 bps. These factors have positively impacted the stock, contributing to its rise.
Image Source: Zacks Investment Research
Factors That May Offset EYE’s Gains
EYE’s business remains vulnerable to growing geopolitical complexities, supply-chain disruptions, shortages of healthcare staff and volatility in capital markets. Additionally, the ongoing changes in U.S. trade policy and retaliatory tariffs look discouraging. All these factors continue to weigh on its profitability. In the fourth quarter of 2025, SG&A expenditures rose 12.1% year over year.
From a solvency viewpoint, National Vision has a significant amount of indebtedness. It exited the fourth quarter of 2025 with cash and cash equivalents of $39 million and short-term debt of $17 million. However, long-term debt was $229 million, much higher than cash levels. This leverage could have several consequences, including greater exposure to adverse economic, industry or competitive developments.
Taking a Look at EYE’s Estimates
The Zacks Consensus Estimate for 2026 EPS has moved north 1 cent in the past 30 days.
The company has an estimated long-term EPS growth rate of 20.1% compared with the industry’s 12.3%.
Other Stocks to Consider
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Edwards Lifesciences (EW - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s negative 0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 15.5% against the industry’s 4.3% fall in the past year.
Intuitive Surgical, flaunting a Zacks Rank #1, has an earnings yield of 2.1% against the industry’s negative 0.7% yield. Shares of the company have risen 1.5% against the industry’s 4.3% fall. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.6% against the industry’s negative 0.7% yield. Shares of the company have climbed 19.1% against the industry’s 4.3% decline. EW’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 5.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
National Vision Gains 129.5% in a Year: What's Driving the Rally?
Key Takeaways
National Vision (EYE - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 129.5%, outperforming the industry’s 12% decline. The S&P 500 composite has increased 23.1% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.
National Vision is a major optical retailer in the United States. As of June 28, 2025, the company operated through a diverse portfolio of 1,240 retail stores across four brands, along with associated omnichannel consumer websites. National Vision operates through one reportable segment, Owned & Host, which includes two owned brands — America’s Best Contacts and Eyeglasses (America’s Best) and Eyeglass World.
Factors Favoring EYE’s Share Price Growth
National Vision’s share price is trending upward, prompted by its strong market share gain in Owned & Host segment. The segment continues to gain from positive comparable store sales growth and new store openings. Of the two Owned brands, America’s Best remains the primary revenue driver.
The company is also driving improvements in Eyeglass World, bringing in a new leadership team earlier in 2025. Further, National Vision leverages remote capabilities to expand exam capacity, with approximately two-thirds of its store base now enabled with remote technology. Its remote hybrid pilot is also progressing well, with more in-store doctors now trained to perform remote exams in other locations. Simultaneously, National Vision is implementing electronic health records to drive expanded capacity, improve in-store efficiencies and improve the patient experience. A solid fourth-quarter performance is also expected to contribute further.
Investors are currently focused on the company’s ongoing strategic transformation. According to management, the transformation initiatives are gaining traction and the strategic focus on key customer segments is driving improvement in its comparable sales. Newly added premium frames like Lam, Ted Baker, Jimmy Choo, HUGO Boss are selling faster than expected. Additionally, the new, refreshed branding unveiled in August 2025 was a major milestone in National Vision's transformation journey.
Meanwhile, National Vision’s 2026 outlook looks encouraging. Net revenues are projected in the range of $2.033-$2.091 billion. Adjusted EPS is estimated to be between 85 cents and $1.09.
Operationally, in the fourth quarter, gross margin expanded 45 basis points (bps) despite a 13.9% rise in the cost of revenues. Also, the operating margin expanded 186 bps. These factors have positively impacted the stock, contributing to its rise.
Image Source: Zacks Investment Research
Factors That May Offset EYE’s Gains
EYE’s business remains vulnerable to growing geopolitical complexities, supply-chain disruptions, shortages of healthcare staff and volatility in capital markets. Additionally, the ongoing changes in U.S. trade policy and retaliatory tariffs look discouraging. All these factors continue to weigh on its profitability. In the fourth quarter of 2025, SG&A expenditures rose 12.1% year over year.
From a solvency viewpoint, National Vision has a significant amount of indebtedness. It exited the fourth quarter of 2025 with cash and cash equivalents of $39 million and short-term debt of $17 million. However, long-term debt was $229 million, much higher than cash levels. This leverage could have several consequences, including greater exposure to adverse economic, industry or competitive developments.
Taking a Look at EYE’s Estimates
The Zacks Consensus Estimate for 2026 EPS has moved north 1 cent in the past 30 days.
The company has an estimated long-term EPS growth rate of 20.1% compared with the industry’s 12.3%.
Other Stocks to Consider
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Edwards Lifesciences (EW - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s negative 0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 15.5% against the industry’s 4.3% fall in the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical, flaunting a Zacks Rank #1, has an earnings yield of 2.1% against the industry’s negative 0.7% yield. Shares of the company have risen 1.5% against the industry’s 4.3% fall. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.6% against the industry’s negative 0.7% yield. Shares of the company have climbed 19.1% against the industry’s 4.3% decline. EW’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 5.5%.